NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

APDN

Applied Dna Sciences Inc

Jul 03 • 04:00PM ET

4.63

Dollar change -0.31
Percentage change -6.19	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN ONC FATE QGEN CRSP EDIT GH NTLA PACB TWST

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-536.64	Insider Own	1.16%	Shs Outstand	0.52M	Perf Week	2.55%
Market Cap	2.40M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.51M	Perf Month	-9.30%
Enterprise Value	-4.19M	PEG	-	EPS next Q	-	Inst Own	5.14%	Short Float	20.44%	Perf Quarter	-80.71%
Income	-46.19M	P/S	0.63	EPS this Y	-	Inst Trans	-	Short Ratio	0.96	Perf Half Y	-97.00%
Sales	3.79M	P/B	0.19	EPS next Y	-	ROA	-66.28%	Short Interest	0.10M	Perf YTD	-96.97%
Book/sh	24.78	P/C	0.35	EPS next 5Y	-	ROE	-141.39%	52W High	2655.00 -99.83%	Perf Year	-98.87%
Cash/sh	13.15	P/FCF	-	EPS past 3/5Y	64.67% 60.68%	ROIC	-441.56%	52W Low	4.36 6.07%	Perf 3Y	-99.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-27.56% -8.63%	Gross Margin	30.51%	Volatility	10.11% 12.64%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-1.11	EPS Y/Y TTM	95.84%	Oper. Margin	-344.11%	ATR (14)	0.79	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	4.27	Sales Y/Y TTM	-31.30%	Profit Margin	-1218.46%	RSI (14)	35.26	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.45	EPS Q/Q	94.22%	SMA20	-5.25%	Beta	-0.03	Target Price	1125.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	5.78%	SMA50	-43.85%	Rel Volume	0.53	Prev Close	4.94
Employees	48	LT Debt/Eq	0.00	Earnings	May 15 AMC	SMA200	-96.61%	Avg Volume	108.44K	Price	4.63
IPO	Oct 18, 2001	Option/Short	No / Yes	EPS/Sales Surpr.	-411.67% -17.01%	Trades		Volume	57,282	Change	-6.19%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-12-21	Initiated	ROTH Capital	Buy	$24
Jan-14-21	Reiterated	H.C. Wainwright	Buy	$18 → $14
Dec-18-20	Reiterated	H.C. Wainwright	Buy	$20 → $12
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$18 → $22
Jul-02-20	Initiated	H.C. Wainwright	Buy	$18
Nov-14-16	Reiterated	Maxim Group	Buy	$8 → $6
May-13-16	Reiterated	Maxim Group	Buy	$13 → $9
Oct-08-15	Reiterated	Maxim Group	Buy	$9 → $13
May-26-15	Initiated	The Benchmark Company	Speculative Buy	$5
Feb-10-15	Reiterated	Maxim Group	Buy	$7 → $9
Jan-13-15	Initiated	Maxim Group	Buy	$7

Show Previous Ratings

Jun-30-25 09:00AM	Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx (ACCESSWIRE) +6.63%
Jun-17-25 04:10PM	Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward (ACCESSWIRE) -7.62%
Jun-16-25 09:00AM	Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August (ACCESSWIRE) +9.52%
May-29-25 04:05PM	Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17 (ACCESSWIRE) -36.88%
08:00AM	Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 (ACCESSWIRE)
05:32PM	Loading…
May-15-25 05:32PM	Applied DNA Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -17.28%
04:05PM	Applied DNA Reports Second Quarter Fiscal 2025 Financial Results (ACCESSWIRE)
May-14-25 11:30AM	Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3 (ACCESSWIRE) +5.62%
Apr-21-25 09:00AM	Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA (ACCESSWIRE)
Apr-08-25 09:00AM	Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) -13.08%
Apr-01-25 09:45AM	Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement (ACCESSWIRE)
Mar-26-25 09:00AM	Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test (ACCESSWIRE)
Mar-12-25 08:00AM	Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025 (ACCESSWIRE) -56.80%
Feb-14-25 02:20AM	Applied DNA Sciences Inc (APDN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com)
Feb-13-25 05:20PM	Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.22%
04:18PM	Loading…
04:18PM	Applied DNA Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress (ACCESSWIRE)
Feb-12-25 12:00PM	Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025 (ACCESSWIRE)
Feb-11-25 08:30AM	Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14 (ACCESSWIRE) +7.34%
Jan-10-25 09:00AM	Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates (ACCESSWIRE)
Jan-08-25 04:30PM	Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter (ACCESSWIRE) -13.46%
Dec-18-24 09:00AM	Applied DNA Customer UHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA (ACCESSWIRE)
09:00AM	Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA (ACCESS Newswire)
Dec-17-24 05:15PM	Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +24.46%
04:12PM	Applied DNA Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines (ACCESSWIRE)
Dec-16-24 10:00AM	Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out (ACCESSWIRE) +12.27%
Oct-30-24 07:15AM	Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -40.56%
Oct-15-24 10:30AM	Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16 (ACCESSWIRE)
Sep-18-24 09:00AM	Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE)
09:15AM	Loading…
Sep-17-24 09:15AM	Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit (ACCESSWIRE)
09:00AM	Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application (ACCESSWIRE)
Sep-11-24 09:00AM	Applied DNA Launches Mpox Clade I and Clade II Testing Service (ACCESSWIRE) +17.97%
Sep-04-24 09:00AM	Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan (ACCESSWIRE) -21.05%
Sep-03-24 11:53PM	Applied DNA Sciences, Inc. (APDN): A Hot Penny Stock On The Move (Insider Monkey) -20.42%
Sep-02-24 12:17PM	10 Hot Penny Stocks On the Move (Insider Monkey)
Aug-23-24 09:00AM	Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I (ACCESSWIRE) +38.80%
Aug-19-24 03:25PM	Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I (ACCESSWIRE) +128.64%
Aug-08-24 04:10PM	Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results (ACCESSWIRE) -6.82%
Aug-07-24 08:00AM	Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024 (ACCESSWIRE) -6.10%
Jul-29-24 11:57AM	CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit (ACCESSWIRE)
11:10AM	Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit (ACCESSWIRE)
Jul-25-24 09:00AM	Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability (ACCESSWIRE)
Jul-18-24 10:00AM	U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract (ACCESSWIRE)
Jul-10-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jul-02-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -19.25%
Jun-27-24 12:00PM	Applied DNA Sciences (APDN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jun-20-24 09:15AM	Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics (ACCESSWIRE) +5.45%
Jun-18-24 09:00AM	Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing (ACCESSWIRE)
Jun-13-24 09:00AM	Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health (ACCESSWIRE) +6.45%
Jun-05-24 09:00AM	Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform (ACCESSWIRE) +16.48%
May-28-24 09:30AM	Applied DNA Announces Pricing of $12 Million Public Offering (ACCESSWIRE) -69.85%
May-13-24 08:55AM	Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML (ACCESSWIRE) -10.72%
May-10-24 08:53PM	APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace) -7.75%
05:15PM	Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results (ACCESSWIRE)
09:00AM	Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE)
May-09-24 05:21AM	Xinjiang cotton widespread despite US UFLPA legislation (Just Style)
May-07-24 12:22PM	Banned Chinese cotton found in 19% of US and global retailers' merchandise, study shows (Reuters)
12:17PM	CORRECTED-Banned Chinese cotton found in 19% of US and global retailers' merchandise, study shows (Reuters)
Apr-25-24 09:00AM	Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program (ACCESSWIRE)
Apr-22-24 04:05PM	Applied DNA Announces 1-For-20 Reverse Stock Split (ACCESSWIRE) -12.12%
Mar-18-24 09:00AM	Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start (ACCESSWIRE) +19.57%
Mar-14-24 10:00AM	Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress (ACCESSWIRE) -23.08%
Feb-21-24 09:40AM	Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year? (Zacks)
Feb-10-24 08:48AM	Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2024 Earnings Call Transcript (Insider Monkey)
Feb-09-24 06:17AM	Q1 2024 Applied DNA Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-08-24 05:40PM	Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:40PM	Applied DNA Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results (ACCESSWIRE)
Feb-05-24 01:00PM	Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024 (ACCESSWIRE)
Feb-02-24 04:15PM	Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE)
Jan-31-24 08:00AM	Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE)
Dec-14-23 08:00AM	Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnologys mRNA Manufacturing Workflow (ACCESSWIRE) -7.89%
Dec-12-23 08:10AM	Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript (Insider Monkey) -19.96%
Dec-07-23 09:55PM	APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -18.43%
04:55PM	Applied DNA Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results (ACCESSWIRE)
Dec-05-23 08:30AM	Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023 (ACCESSWIRE)
Nov-28-23 08:30AM	Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application (ACCESSWIRE)
Nov-16-23 08:30AM	Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA) (ACCESSWIRE) +5.25%
Nov-09-23 09:15AM	Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform (ACCESSWIRE)
Sep-14-23 09:00AM	Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals (ACCESSWIRE)
Sep-06-23 09:00AM	Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs (ACCESSWIRE)
Aug-29-23 09:00AM	Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit (ACCESSWIRE)
Aug-23-23 09:30AM	Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production (ACCESSWIRE) +7.41%
Aug-10-23 04:56PM	Applied DNA Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) +10.06% -10.86%
04:05PM	Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-08-23 08:15AM	ADT (ADT) Q2 Earnings and Revenues Miss Estimates (Zacks)
Aug-07-23 11:00AM	Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023 (ACCESSWIRE)
Jul-27-23 06:24PM	3 Penny Stocks to Buy Before the Breakout (InvestorPlace) +6.62%
Jul-18-23 10:00AM	Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences (ACCESSWIRE)
Jul-13-23 07:15AM	Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach (ACCESSWIRE) +11.81%
Jun-08-23 11:00AM	Applied DNA Announces Presentation at Upcoming Healthcare Investor Conference (ACCESSWIRE) -6.83%
May-16-23 11:53AM	Applied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 04:56PM	Applied DNA Sciences: Fiscal Q2 Earnings Snapshot (AP Finance)
04:05PM	Applied DNA Reports Second Quarter Fiscal 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-03-23 03:00PM	Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023 (Business Wire)
Apr-07-23 12:00PM	Applied DNA's CertainT® Supply Chain Traceability Platform Featured in New York Times Article About the Need for Transparency and Compliance in Global Supply Chains Under Recently Passed U.S. Federal Regulation (Business Wire)
Mar-29-23 09:00AM	Applied DNA Achieves Milestone for Large-Scale linearDNA Production, Delivers Largest Single Shipment by Volume to Date (Business Wire)

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APDN

Applied Dna Sciences Inc

Upgrade your FINVIZ experience